Feed ADXN
AD

Addex Therapeutics Ltd

ADXN · NASDAQ

$3.65 -5.44% (-$0.21)
1M -6.89%
Market Cap CHF 3.73M
P/E Ratio -
Div. Yield -
ROE 131.30%
Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Weak
1/9
Valuation
50 /100
Fair
P/B 1.14x
P/S 50.39x
EV/EBITDA N/A
Growth
4 /100
Declining
Book val. growth 1.00%
Rev. growth 72.38%
FCF growth N/A
Profitability
0 /100
Weak
Net margin 9,410.20%
Op. margin 3,630.79%
FCF margin 3,143.37%
Quality
0 /100
Poor
ROE 131.30%
ROA 146.39%
Asset turnover 0.02x
Debt
54 /100
Moderate
Current ratio 0.97x
Int. coverage -1,432.34x
Debt/Equity 0.03x
Stability
1 /100
Unstable
Rev. volatility 56.78%
EPS volatility 173.14%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ADXN
Online

About the company

Addex Therapeutics Ltd (ADXN) is a Swiss biotechnology company focused on developing innovative drugs for the treatment of neurological and psychiatric disorders. The company leverages advanced technologies targeting allosteric modulation of receptors, enabling it to develop new therapeutic approaches for various conditions such as Parkinson's disease, schizophrenia, and other neurological disorders. Addex Therapeutics is known for its scientific expertise and strong focus on research and development. Addex Therapeutics Ltd (ADXN) shares could be suitable for investors looking for investments in the biotechnology and pharmaceutical research sector with an emphasis on innovative treatment methods.

Sector

Healthcare

Industry

Biotechnology

CEO

Timothy Mark Dyer

Employees

3

Headquarters

Geneva

Upcoming events

09 NOV

Earnings

Upcoming earnings report

42d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.